BioInvent International AB (publ) (STO:BINV)

Sweden flag Sweden · Delayed Price · Currency is SEK
37.45
-0.35 (-0.93%)
Jun 12, 2025, 10:59 AM CET
6.09%
Market Cap 2.49B
Revenue (ttm) 60.80M
Net Income (ttm) -468.06M
Shares Out 65.80M
EPS (ttm) -7.12
PE Ratio n/a
Forward PE 3.88
Dividend n/a
Ex-Dividend Date n/a
Volume 25,572
Average Volume 162,824
Open 37.50
Previous Close 37.80
Day's Range 37.30 - 38.00
52-Week Range 22.70 - 50.80
Beta -0.05
RSI 60.70
Earnings Date Aug 26, 2025

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 114
Stock Exchange Nasdaq Stockholm
Ticker Symbol BINV
Full Company Profile

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.

Financial Statements

News

Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, B...

9 months ago - Benzinga